AG1 RELEASES LATEST UPGRADE OF ITS DAILY HEALTH DRINK, ALONGSIDE RESULTS FROM FOUR PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIALS

AG1 commits an additional $20M to research following the launch of AG1 Next Gen, which has been clinically shown in multiple human clinical studies to close nutrient gaps and support gut health.

NEW YORK, May 1, 2025 /PRNewswire/ -- AG1, the leading global nutrition company, announced today its upgraded formula, AG1 Next Gen, building on a 15 year history of a continuously improved nutrition supplement. This launch is backed by four randomized placebo-controlled, human clinical trials and is accompanied by a continued commitment to more than $20 million in continued research over the next three years.

After years of development, and millions invested in research, the upgraded AG1 formula now includes five clinically studied probiotic strains--Lactobacillus rhamnosus GG, Lactobacillus acidophilus NCFM, Bifidobacterium lactis HN019, Lactobacillus casei LC-11, and Lactobacillus plantarum LP-115--an enhanced methylated B complex, and new and increased vitamins and minerals for even more comprehensive daily support.

The release of AG1 Next Gen comes on the heels of multiple gold-standard clinical trials, demonstrating the formula's positive impact on common nutrient gaps and gut health across a range of diets, ages, and lifestyles. The clinical trials included three double blind, randomized, placebo-controlled human clinical trials along with a triple-blind, randomized, placebo-controlled human clinical trial and showed:

    --  In four of the randomized, placebo-controlled trials, AG1 Next Gen
        demonstrated a positive impact on closing common nutrient gaps.
    --  In a randomized, placebo-controlled trial, AG1 Next Gen increased key
        nutrient levels within three months, including folate and vitamin C.
    --  In three of the randomized, placebo-controlled trials, including
        participants with varying baseline gut health, age, and activity levels,
        AG1 Next Gen on average was shown to increase healthy bacteria in the
        gut by over 10x.
    --  In a randomized, placebo-controlled clinical trial, key nutrients in AG1
        Next Gen were shown to quickly and easily absorb into the body.

As part of AG1's ongoing commitment to innovation and research, the company is committed to investing more than $20 million to support future peer-reviewed, independent research on the complete formula of all future AG1 products, partnerships with leading universities for discovery research focused on advancing nutrition science, and continuing to bolster its in-house team of researchers, clinicians and scientists.

"We are constantly setting a higher bar for ourselves--and consequently the industry," said Kat Cole, Chief Executive Officer at AG1. "The launch of AG1 Next Gen marks years of behind-the-scenes development and research. I'm proud of this milestone of a continuously innovated and improved product, and even more proud of the standards and quality we are elevating in the industry."

Since 2010, AG1 has earned the trust of millions of people globally, from professional and Olympic athletes and world-renowned health experts to those just starting out on their health journey. Each batch undergoes testing for hundreds of contaminants, including toxins, herbicides and pesticides, and heavy metals, and is verified by NSF Certified for Sport®, one of the most rigorous independent quality and safety certification programs in the supplement industry.

For more information about AG1 Next Gen and the full results of the clinical trials, please visit drinkag1.com.

(1) In a triple-blind, randomized, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.

(2) In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome shifts in 20 active adults ages 19-37.

(3) In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome assessments of 24 healthy adults with occasional GI distress ages 26-59.

(4) In a double-blind, randomized, placebo-controlled crossover clinical trial assessing nutrient gaps and bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.

ABOUT AG1
AG1 (formerly Athletic Greens) is a global nutrition company with a mission to empower people to take ownership of their health. The company's flagship product, AG1, is a clinically-studied daily health supplement that combines a high-quality multivitamin, probiotic, and more into a single, powerful scoop. AG1 is NSF Certified for Sport®, one of the most rigorous independent quality and safety certification programs in the supplement industry, and a standard sought by many professional athletes, coaches, and trainers. Founded in 2010, AG1 has operations spanning North America, Europe, and Asia Pacific.

AG1 Media Contact: press@drinkag1.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ag1-releases-latest-upgrade-of-its-daily-health-drink-alongside-results-from-four-placebo-controlled-randomized-clinical-trials-302443590.html

SOURCE AG1